RUBY-3 Clinical Study

Povetacicept (pō-və-tak’-i-sept) is an investigational medication designed to block BAFF (also called BLyS) and APRIL, two molecules called “cytokines” that are thought to be highly involved in the underlying inflammatory processes of IgAN, lupus nephritis, and primary membranous nephropathy. BAFF and APRIL promote the function and survival of many of the body’s immune cells, including B cells that can produce harmful antibodies that cause kidney damage in people with these conditions.

By blocking both BAFF and APRIL, povetacicept is designed to suppress the pathological inflammatory processes underlying these diseases, including antibody-producing B cells and their production of harmful antibodies. It also has the potential to prevent the development of new, harmful immune cells and to prevent, reduce, or even reverse kidney damage associated with IgAN, lupus nephritis, and primary membranous nephropathy.

A clinical study is a type of research using human volunteers. Doctors and scientists conduct clinical studies to find better ways to treat diseases and medical conditions. Each clinical study of an investigational medication like povetacicept is designed to help answer specific questions, such as whether it works and if it is safe. Before a new drug can be authorized and prescribed for a specific condition, it must be evaluated in clinical studies to make sure it is safe and effective.

Participation in a clinical study may provide the opportunity to receive novel treatments, expert care, and additional monitoring from medical staff. It can also offer hope for patients while helping advance science and contributing new knowledge about their disease, which may benefit others in the future.